xml version="1.0" encoding="utf-8"?                

   0000885725 false        0000885725   2021-03-01 2021-03-01     0000885725  us-gaap:CommonStockMember    2021-03-01 2021-03-01     0000885725  bsx:SeniorNoteDue2027Member    2021-03-01 2021-03-01     0000885725  bsx:A550MCPSSeriesAMember    2021-03-01 2021-03-01    iso4217:USD   xbrli:shares     iso4217:USD   xbrli:shares       

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) OF THE 

SECURITIES EXCHANGE ACT OF 1934 

Date of Report (Date of earliest event reported): March 1, 2021 

BOSTON SCIENTIFIC CORPORATION 

(Exact name of registrant as specified in its charter) 

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

(508) 683-4000 

(Registrant's telephone number, including area code) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Securities registered pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share   BSX PR A   New York Stock Exchange  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 ITEM 8.01 OTHER EVENTS.  

Preventice Solutions, Inc. Acquisition 

On March 1, 2021, Boston Scientific Corporation (the “Company”) completed its acquisition of Preventice Solutions, Inc. (“Preventice”). The transaction consists of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment, or approximately $720 million upfront and $230 in a potential milestone payment, after accounting for the Company’s approximately 22 percent equity stake in Preventice prior to completing the acquisition. The Company previously announced entry into a definitive agreement to acquire Preventice on January 21, 2021. Preventice offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors – including short and long-term Holter monitors – to cardiac event monitors and mobile cardiac telemetry. 

Specialty Pharmaceuticals Business Divestiture  

On March 1, 2021, the Company completed the sale of the BTG Specialty Pharmaceuticals Business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for $800 million in cash. The sale follows the definitive agreement announced on December 1, 2020. Boston Scientific acquired the specialty pharmaceuticals business as part of its 2019 acquisition of BTG plc. 

 ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS. 

(d) Exhibits 

 Exhibit No.   Description  

 104    Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document  

SIGNATURE 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED]